- Home
- RADX vs ANTX Comparison
RADX vs ANTX Comparison
Compare RADX & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RADX
- ANTX
- Stock Information
- Founded
- RADX 2021
- ANTX 2017
- Country
- RADX Australia
- ANTX United States
- Employees
- RADX N/A
- ANTX N/A
- Industry
- RADX
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- RADX
- ANTX Health Care
- Exchange
- RADX NYSE
- ANTX Nasdaq
- Market Cap
- RADX 32.5M
- ANTX 33.2M
- IPO Year
- RADX N/A
- ANTX 2022
- Fundamental
- Price
- RADX $4.25
- ANTX $1.07
- Analyst Decision
- RADX Strong Buy
- ANTX Buy
- Analyst Count
- RADX 2
- ANTX 2
- Target Price
- RADX $13.50
- ANTX $2.00
- AVG Volume (30 Days)
- RADX 22.4K
- ANTX 287.9K
- Earning Date
- RADX 02-26-2025
- ANTX 08-12-2025
- Dividend Yield
- RADX N/A
- ANTX N/A
- EPS Growth
- RADX N/A
- ANTX N/A
- EPS
- RADX N/A
- ANTX N/A
- Revenue
- RADX $204,609.00
- ANTX N/A
- Revenue This Year
- RADX N/A
- ANTX N/A
- Revenue Next Year
- RADX N/A
- ANTX N/A
- P/E Ratio
- RADX N/A
- ANTX N/A
- Revenue Growth
- RADX N/A
- ANTX N/A
- 52 Week Low
- RADX $3.50
- ANTX $0.87
- 52 Week High
- RADX $50.82
- ANTX $3.07
- Technical
- Relative Strength Index (RSI)
- RADX N/A
- ANTX 42.84
- Support Level
- RADX N/A
- ANTX $1.07
- Resistance Level
- RADX N/A
- ANTX $1.11
- Average True Range (ATR)
- RADX 0.00
- ANTX 0.04
- MACD
- RADX 0.00
- ANTX 0.00
- Stochastic Oscillator
- RADX 0.00
- ANTX 7.14
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.